GemPharmatech Co Ltd
SSE:688046
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GemPharmatech Co Ltd
Long-Term Debt
GemPharmatech Co Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GemPharmatech Co Ltd
SSE:688046
|
Long-Term Debt
¥35.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Long-Term Debt
¥2.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Long-Term Debt
¥2.2B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Long-Term Debt
¥1.8B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Long-Term Debt
¥1.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
31%
|
CAGR 10-Years
46%
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Long-Term Debt
¥32.2m
|
CAGR 3-Years
172%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GemPharmatech Co Ltd
Glance View
GemPharmatech Co., Ltd. engages in research and development, manufacture, and sale of experimental mouse models. The company is headquartered in Nanjing, Jiangsu and currently employs 1,342 full-time employees. The company went IPO on 2022-04-25. The firm uses gene-editing and other technologies to produce mouse models. The firm also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Company’s products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.
See Also
What is GemPharmatech Co Ltd's Long-Term Debt?
Long-Term Debt
35.6m
CNY
Based on the financial report for Dec 31, 2024, GemPharmatech Co Ltd's Long-Term Debt amounts to 35.6m CNY.
What is GemPharmatech Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
21%
Over the last year, the Long-Term Debt growth was -1%. The average annual Long-Term Debt growth rates for GemPharmatech Co Ltd have been 21% over the past three years .
